Vivoryon Therapeutics NV (VVY) - Total Liabilities

Latest as of December 2025: €2.79 Million EUR ≈ $3.26 Million USD

Based on the latest financial reports, Vivoryon Therapeutics NV (VVY) has total liabilities worth €2.79 Million EUR (≈ $3.26 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore VVY cash flow conversion to assess how effectively this company generates cash.

Vivoryon Therapeutics NV - Total Liabilities Trend (2010–2025)

This chart illustrates how Vivoryon Therapeutics NV's total liabilities have evolved over time, based on quarterly financial data. Check VVY asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Vivoryon Therapeutics NV Competitors by Total Liabilities

The table below lists competitors of Vivoryon Therapeutics NV ranked by their total liabilities.

Company	Country	Total Liabilities
Mishorim Real Estate Investments TA:MSHR	Israel	ILA1.90 Billion
Puloon Technology Inc KQ:094940	Korea	₩7.37 Billion
Domiki Kritis S.A. AT:DOMIK	Greece	€15.20 Million
Barfresh Food Group Inc NASDAQ:BRFH	USA	$11.50 Million
Aurumin Ltd AU:AUN	Australia	AU$2.66 Million
Saeron Auto KO:075180	Korea	₩30.16 Billion
AViTA Corporation TWO:4735	Taiwan	NT$358.63 Million
TechPrecision Corporation Common stock NASDAQ:TPCS	USA	$24.82 Million

Liability Composition Analysis (2010–2025)

This chart breaks down Vivoryon Therapeutics NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Vivoryon Therapeutics NV stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	7.68	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.59	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.37	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Vivoryon Therapeutics NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Vivoryon Therapeutics NV (2010–2025)

The table below shows the annual total liabilities of Vivoryon Therapeutics NV from 2010 to 2025.

Year	Total Liabilities	Change
2025-12-31	€2.79 Million ≈ $3.26 Million	-18.01%
2024-12-31	€3.40 Million ≈ $3.98 Million	-25.14%
2023-12-31	€4.55 Million ≈ $5.32 Million	-6.67%
2022-12-31	€4.87 Million ≈ $5.70 Million	-38.82%
2021-12-31	€7.96 Million ≈ $9.31 Million	+125.58%
2020-12-31	€3.53 Million ≈ $4.13 Million	+10.45%
2019-12-31	€3.20 Million ≈ $3.74 Million	+113313.77%
2018-12-31	€2.82K ≈ $3.29K	+53.24%
2017-12-31	€1.84K ≈ $2.15K	-69.30%
2016-12-31	€5.99K ≈ $7.00K	+4.48%
2015-12-31	€5.73K ≈ $6.70K	+4.07%
2014-12-31	€5.51K ≈ $6.44K	-99.95%
2013-12-31	€10.60 Million ≈ $12.39 Million	+128.41%
2012-12-31	€4.64 Million ≈ $5.42 Million	+11.86%
2011-12-31	€4.15 Million ≈ $4.85 Million	+11.30%
2010-12-31	€3.73 Million ≈ $4.36 Million	--

About Vivoryon Therapeutics NV

AS:VVY Netherlands Biotechnology

Market Cap

$43.28 Million

€37.02 Million EUR

Market Cap Rank

#22990 Global

#83 in Netherlands

Share Price

€1.25

Change (1 day)

+0.40%

52-Week Range

€1.23 - €1.74

All Time High

€26.50